Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622150 | 0.77 | SMN1; SMN2 (0.50) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL990247 | 0.76 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4545218 | 0.75 | SMN1; SMN2 (0.53) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL16967925 | 0.74 | LMNA (0.36) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10906202 | 0.73 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL15322870 | 0.71 | SETD7 (0.44) | SETD7OPRD1ALDH1A1 | |
| SCHEMBL11119754 | 0.71 | ADRB1 (0.44) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL10800823 | 0.71 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL989510 | 0.71 | KMT2A (0.70) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16043321 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3231804-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2268647-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9005578-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | FLUOROPHARMA, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2015-04-09 | — | — | US | disclosed |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | FLUOROPHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8450466-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPTIAL CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| WO-2009117728-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | SETD7 4751/4885MEN1 530/4885KMT2A 2940/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | SETD7 4751/4885MEN1 530/4885KMT2A 2940/4885 |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | SETD7 4751/4885MEN1 530/4885KMT2A 2940/4885 |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | SETD7 4751/4885MEN1 530/4885KMT2A 2940/4885 |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | SETD7 4751/4885MEN1 530/4885KMT2A 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.